Adis Journals and Newsletters

The premier collection of drug-focused medical journals

An invaluable resource for all involved in medical research, practice or teaching, drug regulation or reimbursement, or the pharmaceutical industry

• Independent and reputable publishers of high quality medical journals for over 40 years
• Unique content from the experienced in-house Adis Drug Review team
• Invited review articles summarize complex and broad topics for your end-users
• Cutting-edge original research in all therapy areas

All Adis journal and newsletter content is available on SpringerLink, Springer for R&D, and Springer for Hospitals & Health. These robust, mobile-optimized platforms enable your end users to access over 8 million research documents anytime, anywhere, including thousands of eBooks and more than 400 journals relevant to medical research.
### Clinical Pharmacology and Therapy

<table>
<thead>
<tr>
<th>Title</th>
<th>Impact Factor</th>
<th>Description</th>
</tr>
</thead>
</table>
| **Drugs**                                | 4.343         | • Setting the standards in reviews of all aspects of clinical pharmacology since 1971  
• Definitive reviews of drugs and drug classes, and their place in disease management including systematic reviews and meta-analyses  
• Pivotal original research               |
| **Advances in Therapy**                  | 2.272         | • Dedicated to rapid publication of studies in clinical medicine  
• Reviews and original research across a broad range of therapeutic areas  
• Evaluation of existing and new drug therapies, diagnostics, instrumentation and related fields  
• Enhanced features such as summary slides and animations reinforce reader understanding |
| **Clinical Drug Investigation**          | 1.557         | • A journal focused on clinical investigations of drugs and drug devices  
• Efficacy and safety data from a wide range of clinical trials  
• Outcomes research and pharmacoeconomics studies included |
| **Pharmaceutical Medicine**              | 0.553*        | • Disseminates the latest information on the optimal conduct of clinical studies  
• Contributions from top industry physicians, regulators and academics  
• Topics include regulatory science, pharmacovigilance, ethics, pharmacology and trial design |
| **Drugs & Therapy Perspectives**         | N/A           | • Authoritative yet easy-to-read review articles to aid drug formulary and prescribing decisions  
• New developments and international consensus on drug therapy  
• Guidance on management of adverse drug reactions and interactions  
• Pharmacoeconomics and outcomes research that impacts on clinical practice |

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Title</th>
<th>Impact Factor</th>
<th>Description</th>
</tr>
</thead>
</table>
| **Clinical Pharmacokinetics**            | 5.053         | • Making sense of pharmacokinetic, pharmacodynamic, and pharmacogenetic data  
• Emphasis on clinical data in special populations including those with hepatic or renal impairment, women, children, and the elderly  
• Evidence-based authoritative reviews on new drugs and drug classes |
| **European Journal of Drug Metabolism and Pharmacokinetics** | 1.563 | • Comprehensive journal covering all aspects of pharmacokinetics including drug interactions, bioavailability, and biopharmacy  
• Original research and review articles on special topics  
• Conference proceedings |

*SCImago Cites per Doc. (2y) measures the scientific impact of a journal using the same formula as the Impact Factor but using the Scopus database http://www.scimagojr.com
## Specialist Therapy Areas

<table>
<thead>
<tr>
<th>Title</th>
<th>Impact Factor</th>
<th>Description</th>
</tr>
</thead>
</table>
| CNS Drugs                     | 5.113         | • Drug developments in both neurology and psychiatry  
                                 |                             | • Seminal reviews summarizing wide-ranging and complex original research findings  
                                 |                             | • Succinct guidance on the place of new drugs in clinical practice  
                                 |                             | • Publishes important original research |
| Targeted Oncology             | 4.000         | • A journal for all healthcare professionals in the field of oncology  
                                 |                             | • Reviews of new treatments including monoclonal antibodies and small molecules  
                                 |                             | • Insights into the clinical implications of research into new targets for cancer therapy |
| American Journal of Clinical  | 2.725         | • Content selected to promote evidence-based therapy and effective patient management in clinical dermatology  
                                 |                             | • Definitive reviews on management of dermatological conditions  
                                 |                             | • Clinically relevant original research articles |
| Dermatology                   |               |                                                                                                                                            |
| American Journal of Cardiovascular | 2.422       | • Strong focus on clinical management of cardiovascular disorders  
                                 |                             | • Evidence-based evaluation of novel drugs and new targets  
                                 |                             | • Original clinical and pharmacoeconomic research useful for administrators and decision makers |
| Drugs & Aging                 | 2.838         | • Focused on clinical management of diseases with particular relevance to older adults  
                                 |                             | • Comprehensive reviews and original research promoting optimum drug prescribing and utilization in older patients  
                                 |                             | • Clinical implications of age-related physiological changes for drug therapy |
| Pediatric Drugs               | 1.975         | • Clinical issues affecting drug therapy in children and adolescents  
                                 |                             | • Efficacy and safety of drugs at all stages of pediatric development  
                                 |                             | • Addresses optimal formulations and drug delivery in children  
                                 |                             | • Includes issues surrounding drug access, pharmacogenomics and costs |

*The SCImago Cites per Doc. (2y) measures the scientific impact of a journal using the same formula as the Impact Factor but using the Scopus database http://www.scimagojr.com*
# Health Economics and Outcomes Research

<table>
<thead>
<tr>
<th>Title</th>
<th>Impact Factor</th>
<th>Description</th>
</tr>
</thead>
</table>
| Pharmaco-Economics                 | 2.450         | • Original research on the cost-effectiveness of drug therapy  
• Authoritative reviews on issues related to scarce allocation of resources and formulary management  
• Allows decision makers to critically evaluate and comprehend complex pharmacoeconomic reports |
|                                    |               | Top 50 ISI  
Medline                                                                          |
| The Patient: Patient-Centered Outcomes Research | 1.902         | • Ground-breaking journal published in association with Johns Hopkins University  
• Illuminates what patients value in their treatment, and what drives adherence  
• Provides the latest research on patient-reported outcomes  
• Covers risk communication, shared decision making, and health literacy |
|                                    |               | Top 50 ISI  
Medline                                                                          |
| Applied Health Economics and Health Policy | 1.710*        | • Guide to efficient resource allocation and decision making  
• Economic assessment of various healthcare interventions, systems and policies  
• Range of perspectives, from individual institutions to whole countries |
|                                    |               | Medline                                                                        |
| Pharmaco-Economics & Outcomes News  | N/A           | • Concise summaries on the latest issues in health economics and outcomes news  
• Economic impact of drugs, diseases, devices, diagnostics and screening protocols, prescribing and drug utilisation trends, quality-of-life effects of drugs, reimbursement decisions, and health policy and reforms |
|                                    |               | Top 50 ISI  
Medline                                                                          |

# Pharmacovigilance

<table>
<thead>
<tr>
<th>Title</th>
<th>Impact Factor</th>
<th>Description</th>
</tr>
</thead>
</table>
| Drug Safety                        | 2.824         | • Reviews by leading physicians and academics on benefit-risk assessment, risk management, medication error prevention, and pharmacoepidemiology  
• Specific information on drug use in at-risk patient groups, editorials and commentaries on topical issues, and original research |
|                                    |               | Top 50 ISI  
Medline                                                                          |
| Reactions Weekly                   | N/A           | • A weekly round-up of adverse drug reaction news including pharmacovigilance, regulatory, research, and current opinion  
• Published adverse event case reports, labelling changes, drug withdrawals, and drug safety research  
• First published, drug overdose and drug interaction case reports highlighted for easy reference |

*The SCImago Cites per Doc. (2y) measures the scientific impact of a journal using the same formula as the Impact Factor but using the Scopus database http://www.scimagojr.com
Biotechnology and Precision Medicine

<table>
<thead>
<tr>
<th>Title</th>
<th>Impact Factor</th>
<th>Description</th>
</tr>
</thead>
</table>
| BioDrugs                     | 2.989         | • Independent, definitive reviews on the place of new biologics in clinical practice
|                              |               | • Stem cell therapies
|                              |               | • Emerging treatment strategies and comparative effectiveness |
| Medline                      |               |             |
| Molecular Diagnosis & Therapy| 2.891         | • A journal devoted to the field of personalized medicine
| Medline                      |               | • Simplifies complex research on biomarkers, pharmacogenomics, and molecular diagnostics
|                              |               | • Evaluations of drug/diagnostic combinations
|                              |               | • Genetic factors affecting response to drug therapy |

Key for tables on pages 2, 3, 4 and 5

- Ranked in top 50 of relevant ISI category
- 18 Adis premier journals indexed in Medline

Adis Drug Reviews

Adis Drug Reviews are a unique range of definitive drug assessments written by a specialist in-house team and rigorously peer reviewed by international experts. For more than 40 years these Drug Reviews have been a trusted resource for healthcare practitioners, giving clear guidance on an agent’s place in therapy. The Adis Drug Review program aims to provide readers with the most important and clinically relevant information on the properties of new and established drugs, across all therapeutic areas, and are included in 11 of the Adis Premier Journals.

Adis Drug Evaluations

- Definitive reviews of pharmacological properties, clinical efficacy and tolerability of new and established drugs
- Critical evaluation of the most important data
- Define clinical potential/most appropriate place in therapy

AdisInsight Reports

- Published shortly after the drug receives approval in its first indication in any market
- Brief review of development history, pharmacological properties, clinical efficacy and tolerability
- Based on drug information from the proprietary AdisInsight database

Adis Drug Q&As

- Succinct reviews of pharmacological properties, clinical efficacy and tolerability for the busy practicing clinician or other healthcare professional
- Evidence-based and focus on the practical use of drugs in the clinical setting
- New and established drugs
Adis Journal Archive

- Archive content from 23 high quality Adis Journals and Newsletters including discontinued titles, dating from 1971
- Also available on the SpringerLink, Springer for R&D, and Springer for Hospitals & Health platforms
- Complete, ongoing access for your readers

Open Access Journals

Our Adis Premier Journals are accompanied by a suite of open access journals: the Adis Open and Adis Rapid+ titles. Content includes preclinical, clinical and real-world research in medicine, covering existing and developmental drugs across all therapeutic areas. The journals publish original research, reviews, case reports, and short communications, and are of interest to a wide range of pharmaceutical and healthcare professionals. Adis Open journals include: Drugs in R&D, Drugs - Real World Outcomes and Drug Safety - Case Reports. Adis Rapid+ journals include: Cardiology and Therapy, Dermatology and Therapy, Diabetes Therapy, Infectious Diseases and Therapy, Neurology and Therapy, Ophthalmology and Therapy, Pain and Therapy, Pulmonary Therapy, Rare Cancers and Therapy, and Rheumatology and Therapy.

AdisInsight

Make great discoveries possible in your organization with expertly written content to support drug research and development, disease treatment and decision making.

AdisInsight delivers the most compelling, current scientific and commercial information on drugs in development worldwide, clinical trials, deals and safety reports, in a single easy-to-use database.

Would you like to know more? Contact Springer today.
Visit springer.com/salescontacts to find your local Springer representative!